Clinical aspects of myasthenia explained

Autoimmunity

Volumn 43, Issue 5-6, 2010, Pages 344-352

  Verschuuren, Jan J G M ^a   Palace, Jackie ^b   Erik Gilhus, Nils ^c,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

autoantibody; mutation; Myasthenia gravis; neuromuscular junction; phenotype

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR ANTIBODY; DOK 7 PROTEIN; HLA B7 ANTIGEN; HLA B8 ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; IMMUNOGLOBULIN G3; MUSCLE SPECIFIC KINASE; NICOTINIC RECEPTOR ANTIBODY; PHOSPHOTRANSFERASE; PLECTIN; PROTEIN; PYRIDOSTIGMINE; RAPSYN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANTIBODY RESPONSE; ARTHROGRYPOSIS; CHOLINE ACETYLTRANSFERASE DEFICIENCY; CONGENITAL MYASTHENIC SYNDROME; DIPLOPIA; EATON LAMBERT SYNDROME; ELECTROMYOGRAM; ENZYME DEFICIENCY; EXTRAOCULAR MUSCLE; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE WEAKNESS; MYASTHENIA; MYASTHENIA GRAVIS; NERVE ENDING; NERVE STIMULATION; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; NEWBORN DISEASE; OPHTHALMOPLEGIA; PHENOTYPE; PTOSIS; REVIEW; SEROLOGY; SERONEGATIVE MYASTHENIA GRAVIS; SYNAPSE VESICLE;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; INFANT, NEWBORN; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCLES; MUTATION; MYASTHENIA GRAVIS; MYASTHENIC SYNDROMES, CONGENITAL; NEUROMUSCULAR JUNCTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SYNAPTIC TRANSMISSION;

EID: 77955871486     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003602130     Document Type: Review

References (58)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol 2009;8(5):475-490.
2. Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: A nationwide epidemiologic study. Neurology 2009;73(2):150-151.
3. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: Muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18(5):519-525.
4. Delgado JC, Hameed A, Yunis JJ, Bhol K, Rojas AI, Rehman SB, Khan AA, Ahmad M, Alper CA, Ahmed AR, Yunis EJ. Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Hum Immunol 1997;57(2):110-119.
5. Wirtz PW, Nijnuis MG, Sotodeh M, Willems LNA, Brahim JJ, Putter H, Wintzen AR, Verschuuren JJ. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250(6):698-701.
6. Vincent A, Clover L, Buckley C, Grimley EJ, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psych 2003;74(8):1105-1108.
7. Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psych 2007;78(4): 417-418.
8. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(Pt 10):2304-2311.
9. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother 2009;9(3):351-358.
10. Vincent A. Autoimmune disorders of the neuromuscular junction. Neurol India 2008;56(3):305-313.
11. Chaudhuri A, Behan PO. Myasthenic crisis. QJM Inter J Med 2009;102(2):97-107.
12. Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009;39(4):423-431.
13. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom- Davis J, Kennett R, Hilton-JonesD, Matthews PM, Vincent A. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006;129(Pt 6):1481-1492.
14. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibodynegative MG. Ann Neurol 2005;57(3):444-448.
15. Saka E, Topcuoglu MA, Akkaya B, Galati A, Onal MZ, Vincent A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;65(5): 782-783.
16. Niks EH, Kuks JB, Roep BO, Haasnoot GW, Verduijn W, Ballieux BE, De Baets MH, Vincent A, Verschuuren JJ. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66(11):1772-1774.
17. Niks EH, van Leeuwen Y, Leite MI, Dekker FW,Wintzen AR, Wirtz PW, Vincent A, van Tol MJD, Zijde CMJV, Verschuuren JJGM. Clinical fluctuations inMuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008;195(1-2):151-156.
18. McConville J, Farrugia ME, BeesonD, KishoreU, Metcalfe R, Newsom-Davis J, Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55(4):580-584. (Pubitemid 38391977)
19. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131(Pt 7):1940-1952. (Pubitemid 351957451)
20. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti- N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147(1):35-42.
21. Oneill JH, Murray NMF, Newsomdavis J. The Lambert- Eaton myasthenic syndrome-A review of 50 cases. Brain 1988;111:577-596.
22. Wirtz PW, Sotodeh M, Nijnuis M, van Doorn PA, van Engelen BGM, Hintzen RQ, De Kort PLM, Kuks JB, Twijnstra A, De Visser M, Visser LH,Wokke JH, Wintzen AR, Verschuuren JJ. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psych 2002;73(6):766-768.
23. Titulaer MJ, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome - Tumor versus nontumor forms. AnnNYAcad Sci 2008;1132:129-134.
24. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353(9147):117-118.
25. Oskoui M, Jacobson L, Chung WK, Haddad J, Vincent A, Kaufmann P, De Vivo DC. Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis. Neurology 2008;71(24):2010-2012.
26. Niks EH, Verrips A, Semmekrot BA, Prick MJ, Vincent A, van TolMJ, Jol-Van Der Zijde CM, Verschuuren JJ. A transient neonatal myasthenic syndrome with anti-musk antibodies. Neurology 2008;70(14):1215-1216.
27. Reuner U, Kamin G, Ramantani G, Reichmann H, Dinger J. Transient neonatal Lambert-Eaton syndrome. J Neurol 2008; 255(11):1827-1828.
28. Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, Vernet-der GB, Eymard B, Newsom-Davis J. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98(10):2358-2363.
29. Bever CT, Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983;14(5): 516-519.
30. Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993;84(4):309-333.
31. Cucurachi L, Cattaneo L, Gemignani F, Pavesi G. Late onset generalized myasthenia gravis presenting with facial weakness and bulbar signs without extraocular muscle involvement. Neurol Sci 2009;30:343-344.
32. Guglieri M, Straub V, Bushby K, Lochmuller H. Limb-girdle muscular dystrophies. Curr Opin Neurol 2008;21(5): 576-584.
33. Shih HP, Gross MK, Kioussi C. Muscle development: Forming the head and trunk muscles. Acta Histochem 2008; 110(2):97-108.
34. Wai Yu, Man CY, Chinnery PF, Griffiths PG. Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 2005;15(1):17-23.
35. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Andrade FH. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001;98(21):12062-12067.
36. Groen WB, Leen WG, Vos AM, Cruysberg JR, van Doorn PA, van Engelen BG. Ptosis as a feature of late-onset glycogenosis type II. Neurology 2006;67(12):2261-2262.
37. Rodolico C, Toscano A, Autunno M, Messina S, Nicolosi C, Aguennouz M, Laura M, Girlanda P, Messina C, Vita G. Limb-girdle myasthenia: Clinical, electrophysiological and morphological features in familial and autoimmune cases. Neuromusc Disord 2002;12(10):964-969.
38. Oh SJ, Kuruoglu R. Chronic limb-girdle myasthenia gravis. Neurology 1992;42(6):1153-1156.
39. Nations SP, Wolfe GI, Amato AA, Jackson CE, Bryan WW, Barohn RJ. Distal myasthenia gravis. Neurology 1999;52(3): 632-634.
40. Mihaylova V, Muller JS, Vilchez JJ, Salih MA, Kabiraj MM, D'Amico A, Bertini E, Wolfle J, Schreiner F, Kurlemann G, Rasic VM, Siskova D, Colomer J, Herczegfalvi A, Fabriciova K, Weschke B, Scola R, Hoellen F, Schara U, Abicht A, Lochmuller H. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008;131(Pt 3):747-759.
41. Wintzen AR, Plomp JJ, Molenaar PC, van Dijk JG, van Kempen GT, Vos RM, Wokke JH, Vincent A. Acquired slow-channel syndrome: A form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann Neurol 1998;44(4):657-664.
42. Scola RH, Werneck LC, Iwamoto FM, Comerlato EA, Kay CK. Acquired slow-channel syndrome. Muscle Nerve 2000;23(10):1582-1585.
43. Bady B, Chauplannaz G, Carrier H. Congenital Lambert- Eaton myasthenic syndrome. J Neurol Neurosurg Psych 1987; 50(4):476-478.
44. Ohno K, Tsujino A, Brengman JM, Harper CM, Bajzer Z, Udd B, Beyring R, Robb S, Kirkham FJ, Engel AG. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci USA 2001;98(4):2017-2022.
45. Conomy JP, Levinsohn M, Fanaroff A. Familial infantile myasthenia gravis: A cause of sudden death in young children. J Pediatr 1975;87(3):428-430.
46. Maselli RA, Chen D, Mo D, Bowe C, Fenton G, Wollmann RL. Choline acetyltransferase mutations in myasthenic syndrome due to deficient acetylcholine resynthesis. Muscle Nerve 2003;27(2):180-187.
47. Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez CM, Richman DP, Wollmann RL. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology 2001;57(2):279-289.
48. Walls TJ, Engel AG, Nagel AS, Harper CM, Trastek VF. Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reduced quantal release. Ann N Y Acad Sci 1993;681:461-468.
49. Maselli RA, Ng JJ, Anderson JA, Cagney O, Arredondo J, Williams C, Wessel HB, Abdel-Hamid H, Wollmann RL. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 2009;46(3): 203-208.
50. Richard P, Gaudon K, Haddad H, Ben Ammar A, Genin E, Bauche S, Paturneau-Jouas M, Muller JS, Lochmueller H, GridD, Hamri A, Nouioua S, Tazir M, MayerM, Desnuelle C, Barois A, Chabrol B, Pouget J, Koenig J, Gouider-Khouja N, Hentati F, Eymard B, Hantai D. The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa. Neurology 2008;71(24):1967-1972.
51. Shen XM, Ohno K, Fukudome T, Tsujino A, Brengman JM, De Vivo DC, Packer RJ, Engel AG. Congenital myasthenic syndrome caused by low-expressor fast-channel AChR delta subunit mutation. Neurology 2002;59(12):1881-1888.
52. Webster R, Brydson M, Croxen R, Newon-Davis J, Vincent A, Beeson D. Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome. Neurology 2004;62(7):1090-1096.
53. Burke G, Cossins J, Maxwell S, Owens G, Vincent A, Robb S, Nicolle M, Hilton-Jones D, Newsom-Davis J, Palace J, Beeson D. Rapsyn mutations in hereditary myasthenia- Distinct early- and late-onset phenotypes. Neurology 2003; 61(6):826-828.
54. Muller JS, Mildner G, Muller-FelberW, ScharaU, Krampfl K, Petersen B, Petrova S, Stucka R, Mortier W, Bufler J, Kurlemann G, Huebner A, Merlini L, Lochmuller H, Abicht A. Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients. Neurology 2003; 60(11):1805-1810.
55. Tsujino A, Maertens C, Ohno K, Shen XM, Fukuda T, Harper CM, Cannon SC, Engel AG. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci USA 2003;100(12):7377-7382.
56. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol 1999;58(8):832-846.
57. Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R, Jayawant S, Yamanashi Y, Beeson D. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 2007;130(Pt 6):1507-1515.
58. Selcen D, Milone M, Shen XM, Harper CM, Stans AA, Wieben ED, Engel AG. Dok-7 myasthenia: Phenotypic and molecular genetic studies in 16 patients. Ann Neurol 2008; 64(6):S153-S154.